康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組

阿斯達克財經

2025/03/06

康方生物(09926.HK) 宣佈，自主研發的全球首創PD-1/CTLA-4雙抗新藥卡度尼利「開坦尼」，用於高復發風險肝細胞癌(HCC)根治術或消融後輔助治療的註冊性三期臨牀研究，近日已完成全部患者入組。目前卡度尼利配合侖伐替尼和經肝動脈化療栓塞(TACE)用於治療中晚期不可切除HCC的註冊三期臨牀研究也在進行中，公司預期，卡度尼利可望成為早期和中晚期HCC患者全方位且更有效率的疾病解決方案。...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517039419"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517039419\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517039419?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","is_english":false,"pubTime":"2025-03-06 10:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517039419","market":"hk","top_or_hot":-1,"title":"康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組","media":"阿斯達克財經","content":"<div>\n<p>康方生物(09926.HK) 宣佈，自主研發的全球首創PD-1/CTLA-4雙抗新藥卡度尼利「開坦尼」，用於高復發風險肝細胞癌(HCC)根治術或消融後輔助治療的註冊性三期臨牀研究，近日已完成全部患者入組。目前卡度尼利配合侖伐替尼和經肝動脈化療栓塞(TACE)用於治療中晚期不可切除HCC的註冊三期臨牀研究也在進行中，公司預期，卡度尼利可望成為早期和中晚期HCC患者全方位且更有效率的疾病解決方案。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-03-06 10:33</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>康方生物(09926.HK) 宣佈，自主研發的全球首創PD-1/CTLA-4雙抗新藥卡度尼利「開坦尼」，用於高復發風險肝細胞癌(HCC)根治術或消融後輔助治療的註冊性三期臨牀研究，近日已完成全部患者入組。目前卡度尼利配合侖伐替尼和經肝動脈化療栓塞(TACE)用於治療中晚期不可切除HCC的註冊三期臨牀研究也在進行中，公司預期，卡度尼利可望成為早期和中晚期HCC患者全方位且更有效率的疾病解決方案。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348783233.USD","symbol_name":"安聯東方收入型 CI A Dis美元","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN","article_id":"2517039419","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2517039419","pubTimestamp":1741228380,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"康方生物宣佈，自主研發的全球首創PD-1/CTLA-4雙抗新藥卡度尼利「開坦尼」，用於高復發風險肝細胞癌根治術或消融後輔助治療的註冊性三期臨牀研究，近日已完成全部患者入組。目前卡度尼利配合侖伐替尼和經肝動脈化療栓塞用於治療中晚期不可切除HCC的註冊三期臨牀研究也在進行中，公司預期，卡度尼利可望成為早期和中晚期HCC患者全方位且更有效率的疾病解決方案。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348783233.USD":"安联东方收入型 CI A Dis美元","09926":"康方生物","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"Akeso Biotech (09926. HK) completed patient enrollment in phase III clinical trials with cardonilid in the treatment of hepatocellular carcinoma with high risk of recurrence","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"康方生物(09926.HK) 宣佈，自主研發的全球首創PD-1/CTLA-4雙抗新藥卡度尼利「開坦尼」，用於高復發風險肝細胞癌(HCC)根治術或消融後輔助治療的註冊性三期臨牀研究，近日已完成全部患者入組。目前卡度尼利配合侖伐替尼和經肝動脈化療栓塞(TACE)用於治療中晚期不可切除HCC的註冊三期臨牀研究也在進行中，公司預期，卡度尼利可望成為早期和中晚期HCC患者全方位且更有效率的疾病解決方案。卡度尼利針對胃癌、肺癌、肝癌、子宮頸癌、胰臟癌等瘤種的16個適應症已經進行超過23項臨牀研究，針對復發/轉移性子宮頸癌和第一線胃癌適應症已獲批上市。(gc/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-05 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}